Hereditary Breast And Ovarian Cancer Testing at CENTOGENE
Breast-ovarian cancer is one of the most common cancers in the world affecting ~12.5% of woman during their lifetime. Advances in genetic testing have led to the identification of numerous genes associated with inherited susceptibility to breast and/or ovarian cancer. Mutations in the BRCA1 and BRCA2 genes account for 50-85% of hereditary breast/ovarian cancers. In patients with a negative BRCA1 or BRCA2 result, other cancer predisposition genes may be considered and additional testing may be appropriate.
Genetic testing for inherited breast/ovarian cancer at CENTOGENE enables you to make informed decisions on preventive actions which can mean a better overall prognosis through a choice of surgical and non-surgical treatment options.
At CENTOGENE, we have analyzed over the past years thousands of breast-ovarian cancer patient's samples from all over the world. This medical expertise, combined with the constant optimization of our internal processes and implementation of new diagnostic techniques, gives us the opportunity to support you with an attractive new diagnostic offer for genetic testing of breast-ovarian cancers.
CentoBreast® is a comprehensive panel that is intended for genetic testing of hereditary breast-ovarian cancers caused by mutations in the genes most commonly associated with breast/ovarian cancer: BRCA1 and BRCA2, and other high penetrance genes (TP53, PTEN, STK11, CDH1), intermediate-risk associated genes (PALB2, CHEK2, ATM) and low-risk associated genes (NBN, BARD1, BRIP1, RAD51C) that are associated with breast-ovarian cancer. Using NGS bidirectional sequencing of the full genes from the panel, including all exons, exon/intron boundaries and promoter regions, with additional Sanger-sequencing confirmation for every detected genetic variant, we are enabling 100% mutation detection reproducibility for Sanger sequencing.
For more information, please download our information brochure.